GlaxoSmithKline has secured rights to a technology, developed in
partnership with US company Advaxis, could improve the
effectiveness of vaccine-based treatments for cancer.
Pharmaceutical major GlaxoSmithKline has set aside £1 million
(€1.4m) to soften the blow of selling its bulk active ingredient
manufacturing facility in Montrose.
Novartis has agreed to pay GlaxoSmithKline a royalty on sales of a
generic version of GSK's antibiotic Augmentin
(amoxicillin/clavulanate) sold in the USA as AmoxC.
GlaxoSmithKline has opened an ultra-high-throughput screening
facility at its site in Tres Cantos, Spain, marking a significant
milestone in the company's bid to develop a more industrialised
approach to the process of drug discovery.